UCB Australia

30 PBAC submissions on file, active 2008–2025. 83% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Certolizumab pegol
  Rheumatology · Recommended with restriction · 2019—
• Bimekizumab
  Dermatology · Recommended · 2025—
• Lacosamide
  Neurology · Recommended with restriction · 2021—
• Brivaracetam
  Neurology · Recommended with restriction · 2019—
• Zilucoplan
  Neurology · Not recommended · 2025—
• Fenfluramine
  Neurology · Recommended with restriction · 2024—
• Levetiracetam
  Neurology · Recommended with restriction · 2008—
• Rotigotine
  Neurology · Not recommended · 2008—
• Rozanolixizumab
  Neurology · Recommended with restriction · 2025—

Therapy area mix

Activity by year

2008 (2) · 2010 (1) · 2011 (1) · 2012 (1) · 2014 (2) · 2015 (1) · 2016 (2) · 2017 (3) · 2018 (1) · 2019 (4) · 2021 (1) · 2022 (1) · 2023 (1) · 2024 (5) · 2025 (4)

Rejection patterns

Across 5 Not recommended decisions on file.

• 1×lack of robust clinical data for the proposed indication
• 1×inadequate transitivity between brivaracetam and lacosamide trials
• 1×concern over how brivaracetam would be used in clinical practice and appropriateness of nominated comparator
• 1×unreliable post hoc subgroup analysis results
• 1×inadequately supported non-inferiority claims for both efficacy and safety